On CNBC’s “Halftime Report Final Trades,” Liz Young of BNY Mellon Investment Management highlighted the Health Care Select Sector SPDR Fund XLV as her final trade.
Joshua Brown of Ritholtz Wealth Management selected Pfizer Inc. PFE, which bottomed in the middle of December.
At the JPMorgan Healthcare Conference, Pfizer CEO Albert Bourla expressed the company’s determination to navigate through the burgeoning obesity market, despite setbacks involving a terminated weight-loss drug candidate due to severe side effects.
Don’t forget to check out our premarket coverage here
Karen Firestone of Aureus Asset Management chose Autodesk, Inc. ADSK.
Keybanc analyst Jason Celino, last week, upheld Autodesk with an Overweight rating and raised the price target from $245 to $260.
Bill Baruch of Blue Line Futures named AbbVie Inc. ABBV as his final trade.
Enigma Biomedical Group – USA executed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie’s Novel 4R Tau PET Imaging Biomarkers. AbbVie is anticipated to disclose its full-year and fourth-quarter 2023 financial results on Feb. 2, 2024, before the opening bell.
Analysts anticipate the company to report quarterly earnings at $2.9 per share on revenue of $13.99 billion.
Price Performance
- Health Care Select Sector SPDR Fund declined by 0.01%.
- Pfizer shares fell by 0.2% to close at $28.09 on Thursday.
- Autodesk gained 1.1% to reach $241.18.
- AbbVie increased by 0.8% to $163.30 during Thursday’s session.
Check This Out: Top 3 Defensive Stocks That May Fall Off A Cliff This Quarter
Image: Shutterstock
